Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
GSK (NYSE:GSK) has entered into strategic agreements with Hengrui Pharma to develop up to 12 innovative medicines in Respiratory, Immunology & Inflammation, and Oncology. GSK will pay $500 million in upfront fees and potential milestone payments of up to $12 billion.
The deal includes an exclusive worldwide license (excluding Greater China region) for HRS-9821, a potential best-in-class PDE3/4 inhibitor for COPD treatment. Additionally, Hengrui will develop 11 other programs through Phase I, with GSK holding exclusive options for worldwide commercialization rights.
HRS-9821 has shown promising results in early clinical studies, demonstrating potent bronchodilation and anti-inflammatory effects, with the potential for convenient dry-powder inhaler formulation.
GSK (NYSE:GSK) ha stipulato accordi strategici con Hengrui Pharma per sviluppare fino a 12 farmaci innovativi nei settori Respiratorio, Immunologia e Infiammazione, e Oncologia. GSK verser脿 500 milioni di dollari come pagamento iniziale e potenziali pagamenti milestone fino a 12 miliardi di dollari.
L'accordo prevede una licenza esclusiva mondiale (esclusa la regione della Grande Cina) per HRS-9821, un potenziale inibitore PDE3/4 di prima classe per il trattamento della BPCO. Inoltre, Hengrui svilupper脿 altri 11 programmi fino alla fase I, con GSK che detiene opzioni esclusive per i diritti di commercializzazione a livello mondiale.
HRS-9821 ha mostrato risultati promettenti negli studi clinici preliminari, dimostrando potenti effetti broncodilatatori e anti-infiammatori, con il potenziale per una formulazione comoda in inalatore a polvere secca.
GSK (NYSE:GSK) ha firmado acuerdos estrat茅gicos con Hengrui Pharma para desarrollar hasta 12 medicamentos innovadores en Respiratorio, Inmunolog铆a e Inflamaci贸n, y Oncolog铆a. GSK pagar谩 500 millones de d贸lares como tarifa inicial y posibles pagos por hitos de hasta 12 mil millones de d贸lares.
El acuerdo incluye una licencia exclusiva mundial (excluyendo la regi贸n de Gran China) para HRS-9821, un posible inhibidor PDE3/4 de primera clase para el tratamiento de la EPOC. Adem谩s, Hengrui desarrollar谩 otros 11 programas hasta la Fase I, con GSK teniendo opciones exclusivas para los derechos de comercializaci贸n a nivel mundial.
HRS-9821 ha mostrado resultados prometedores en estudios cl铆nicos tempranos, demostrando potentes efectos broncodilatadores y antiinflamatorios, con potencial para una formulaci贸n conveniente en inhalador de polvo seco.
GSK (NYSE:GSK)电� Hengrui Pharma鞕� 順疙潯旮�, 氅挫棴頃� 氚� 鞐检, 膦呾枒頃� 攵勳暭鞐愳劀 斓滊寑 12臧滌潣 順侅嫚 鞁犾暯 臧滊皽鞚� 鞙勴暅 鞝勲灥鞝� 瓿勳暯鞚� 觳搓舶頄堨姷雼堧嫟. GSK电� 5鞏� 雼煬鞚� 靹犼笁旮堦臣 斓滊寑 120鞏� 雼煬鞚� 毵堨澕鞀ろ啢 歆�旮夑笀鞚� 歆�攵堩暊 鞓堨爼鞛呺媹雼�.
鞚措矆 瓿勳暯鞐惖鐢 COPD 旃橂毳� 鞙勴暅 鞛犾灛鞝� 斓滉碃 靾橃鞚� PDE3/4 鞏奠牅鞝滌澑 HRS-9821鞐� 雽�頃� 欷戧淡 雽�毳� 歆�鞐潉 鞝滌櫢頃� 鞝� 靹戈硠 霃呾爯 霛检澊靹犾姢臧� 韽暔霅橃柎 鞛堨姷雼堧嫟. 霕愴暅, Hengrui电� 11臧滌潣 於旉皜 頂勲攴鸽灗鞚� 1靸侁箤歆� 臧滊皽頃橂┌, GSK电� 鞝� 靹戈硠 靸侅梾頇� 甓岆Μ鞐� 雽�頃� 霃呾爯 鞓奠厴鞚� 氤挫湢頃╇媹雼�.
HRS-9821鞚� 齑堦赴 鞛勳儊 鞐瓣惮鞐愳劀 臧曤牓頃� 旮瓣磤歆� 頇曥灔 氚� 頃椉 須臣毳� 氤挫棳欤检棃鞙茧┌, 韼鸽Μ頃� 瓯挫“ 攵勲 頋§瀰旮� 鞝滍槙 臧�電レ劚鞚� 臧�歆�瓿� 鞛堨姷雼堧嫟.
GSK (NYSE:GSK) a conclu des accords strat茅giques avec Hengrui Pharma pour d茅velopper jusqu'脿 12 m茅dicaments innovants dans les domaines Respiratoire, Immunologie & Inflammation, et Oncologie. GSK versera 500 millions de dollars en frais initiaux et des paiements d'茅tape potentiels pouvant atteindre 12 milliards de dollars.
L'accord comprend une licence exclusive mondiale (脿 l'exclusion de la r茅gion de la Grande Chine) pour HRS-9821, un inhibiteur PDE3/4 potentiel de premier plan pour le traitement de la BPCO. De plus, Hengrui d茅veloppera 11 autres programmes jusqu'脿 la Phase I, avec GSK d茅tenant des options exclusives pour les droits de commercialisation mondiaux.
HRS-9821 a montr茅 des r茅sultats prometteurs lors d'茅tudes cliniques pr茅coces, d茅montrant des effets bronchodilatateurs puissants et anti-inflammatoires, avec un potentiel pour une formulation pratique en inhalateur 脿 poudre s猫che.
GSK (NYSE:GSK) hat strategische Vereinbarungen mit Hengrui Pharma getroffen, um bis zu 12 innovative Medikamente in den Bereichen Atemwege, Immunologie & Entz眉ndung sowie Onkologie zu entwickeln. GSK wird 500 Millionen US-Dollar als Vorauszahlung und potenzielle Meilensteinzahlungen von bis zu 12 Milliarden US-Dollar leisten.
Der Vertrag beinhaltet eine exklusive weltweite Lizenz (ausgenommen der Gro脽china-Region) f眉r HRS-9821, einen potenziellen erstklassigen PDE3/4-Inhibitor zur COPD-Behandlung. Zus盲tzlich wird Hengrui 11 weitere Programme bis zur Phase I entwickeln, wobei GSK exklusive Optionen f眉r weltweite Vermarktungsrechte h盲lt.
HRS-9821 hat in fr眉hen klinischen Studien vielversprechende Ergebnisse gezeigt, mit starken bronchodilatatorischen und antiinflammatorischen Wirkungen sowie dem Potenzial f眉r eine praktische Trockenpulverinhalator-Formulierung.
- Strategic acquisition of potential best-in-class COPD treatment (HRS-9821)
- Rights to develop up to 11 additional innovative medicines
- Expands GSK's growth opportunities beyond 2031
- Leverages Hengrui's early discovery capabilities with GSK's global development expertise
- Significant upfront cost of $500 million
- Substantial future milestone payments up to $12 billion
- Excludes rights in Greater China region
- Deal subject to regulatory clearances including Hart-Scott-Rodino Act
Insights
GSK's strategic $500M deal with Hengrui expands pipeline through 2031+ with promising respiratory and oncology assets.
GSK's comprehensive partnership with Hengrui Pharma represents a significant pipeline-building strategy with immediate and long-term implications. The centerpiece is HRS-9821, a potential best-in-class PDE3/4 inhibitor for COPD that addresses an important therapeutic gap in GSK's respiratory portfolio by targeting patients with persistent dyspnea regardless of background therapy. The drug's dual mechanism provides both bronchodilation and anti-inflammatory effects, while its dry-powder inhaler formulation aligns perfectly with GSK's established delivery systems.
The deal's structure is particularly shrewd 鈥� $500 million upfront secures 12 potential assets while deferring significant capital deployment until after phase I results demonstrate viability. This de-risked approach with option-based economics for 11 additional programs allows GSK to selectively advance only the most promising candidates while leveraging Hengrui's efficient early-stage development capabilities.
The $12 billion in potential milestone payments signals ambitious expectations but is appropriately structured as success-based compensation. For GSK, this collaboration strategically addresses the critical 2031+ growth window when current blockbusters face patent expirations. Meanwhile, Hengrui gains valuable development expertise and global commercialization capabilities outside their home markets while retaining rights in China and surrounding regions.
This agreement exemplifies the evolving pharmaceutical partnership model that combines Western market access with Chinese innovation capacity, creating a capital-efficient pathway to expand therapeutic pipelines with reduced upfront risk. The focus on validated targets increases probability of success while still pursuing potential best-in-class profiles.
- Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD
- Additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK following phase I completion
The agreements include an exclusive worldwide license (excluding mainland
HRS-9821 has demonstrated potent PDE3 and PDE4 inhibition, leading to increased bronchodilation and anti-inflammatory effects in early clinical and preclinical studies. In addition, HRS-9821 provides the opportunity for a convenient dry-powder inhaler (DPI) formulation that strategically fits GSK's established inhaled portfolio.
The agreements also include a pioneering scaled collaboration to generate up to 11 programmes in addition to HRS-9821, each with its own financial structure. Hengrui Pharma will lead the development of these programmes up to completion of phase I trials, including patients outside of
Frank Jiang, Executive Vice President and Chief Strategy Officer of Hengrui Pharma, said: "This strategic collaboration with GSK marks yet another significant milestone in Hengrui's globalisation journey and our mission to innovate and deliver higher-quality, cutting-edge therapies for patients worldwide. GSK brings additional R&D expertise, a robust global clinical network, and broad regulatory capabilities that will accelerate our PDE3/4 inhibitor as well as an array of other innovative therapy programs to overseas markets, potentially delivering breakthrough treatments to patients globally."
Tony Wood, Chief Scientific Officer, GSK said: "We're delighted to announce these exciting agreements with Hengrui Pharma which complement our already-extensive pipeline. This deal reflects our strategic investment in programmes that address validated targets, increasing the likelihood of success, and with the option to advance those assets with the greatest potential for patient impact."
The collaboration enables scale and speed to proof-of-concept to develop up to 11 additional innovative medicines. It benefits from GSK's therapy area expertise, deep understanding of disease biology, clinical development capability and global commercial scale with Hengrui Pharma's early discovery engine, platform technologies, extensive pre-clinical pipeline of high-value programmes and speed of clinical evaluation.
Financial considerations
GSK will pay
The license to HRS-9821 is subject to customary conditions, including applicable regulatory agency clearances under the Hart-Scott-Rodino Act in the US.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
About Hengrui Pharma
Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialisation of high-quality medicines to address unmet clinical needs. With a global R&D team that includes 14 R&D centres and more than 5,500 professionals, Hengrui Pharma's therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. To date, Hengrui has commercialised 23 new molecular entity drugs and 4 other innovative drugs in
Media on behalf of Hengrui Pharma:
DGA Group
[email protected]
View original content:
SOURCE Jiangsu Hengrui Pharmaceuticals Co., Ltd
FAQ
What is the value of the GSK-Hengrui Pharma collaboration deal?
What is HRS-9821 and how will it benefit GSK's portfolio?
How many programs are included in the GSK-Hengrui collaboration?
What territories are covered in the GSK-Hengrui partnership?
When will the GSK-Hengrui deal be completed?
